2022 Agenda
(Oncology - December 2022)
WEDNESDAY, DECEMBER 14, 2022
All Times are EST Time Zone
8:30am // REGISTRATION AND BREAKFAST
9:00am // OPENING REMARKS
9:10am // KEYNOTE TALK - Greg Simon, Former Director of the Biden Cancer Initiative and Policy Director at Pfizer. TOPIC: Cancer Policy Under the Biden Administration
9:40am // Corporate Presentation - Onconova Therapeutics (NASDAQ:ONTX)
10:00am // Corporate Presentation - Link Immunotherapeutics
10:20am // Corporate Presentation - Tactical Therapeutics
10:40am // Corporate Presentation - TibaRay Medical Systems
11:00am // Corporate Presentation - Chimera Bio
11:20am // Corporate Presentation - Innova Therapeutics
11:40pm // Corporate Presentation - Starpax Biopharma
12:00pm // Corporate Presentation - SmartBreast Corporation
12:20pm // Corporate Presentation - Revere Pharmaceuticals
12:40pm // SPEAKER - Dr. Aditya Bardia, Director Breast Cancer Research Program, Mass General. TOPIC: The Development of Sacituzumab Govitecan (TRODELVY)
1:10pm // LUNCH BREAK / CEO WORKSHOP
1:20pm // CEO WORKSHOP - Achieving Commercial Success with the NIH as a Strategic Partner. Curators: Dr. Michael Salgaller, Director of Tech Transfer, NCI | Supervisor, Invention Development and Marketing Unit (IDMU); Steve Ferguson, Deputy Director, Licensing and Entrepreneurship, National Institutes of Health
2:30pm // Corporate Presentation - SynDevRx
2:50pm // Corporate Presentation - Enterome
3:10pm // Corporate Presentation - Curadigm
3:30pm // Corporate Presentation - Alyra Therapeutics
3:50pm // Corporate Presentation - CasInvent Pharma
4:10pm // Corporate Presentation - BioVaxys Technology
4:30pm // Corporate Presentation - M.T.3 USA
4:50pm // Corporate Presentation - Neomics Pharmaceuticals
5:10pm // Corporate Presentation - Rapa Therapeutics
5:30pm // Corporate Presentation - Geneius Biotechnology
5:50pm // SPEAKER - Dr. Neil Iyengar, Medical Oncologist, Memorial Sloan. TOPIC: The Cross-Section of Obesity, Diabetes, and Cancer
6:20pm // CLOSING REMARKS
6:30pm // DINNER RECEIPTION
THURSDAY, DECEMBER 15, 2022
All Times are EST Time Zone
8:30am // REGISTRATION AND BREAKFAST
9:00am // OPENING REMARKS
9:10am // KEYNOTE TALK - Dr. Ronan O'Hagan. CEO, Bectas. Former CSO, Xilio. Former Director Oncology Drug Development, Merck. TOPIC: Oncology Drug Development.
9:40am // Corporate Presentation - Bectas Therapeutics
10:00am // Corporate Presentation - Bespoke Biotherapeutics
10:20am // Corporate Presentation - Elpis Biopharmaceuticals
10:40am // Corporate Presentation - LabyRx Immuno-Oncology
11:00am // Corporate Presentation - Canget BioTekpharma
11:20am // Corporate Presentation - NuvOx Pharma
11:40am // Corporate Presentation - Thrive Bio
12:00pm // Corporate Presentation - Leapfrog Bio
12:20pm // Corporate Presentation - Vetigenics
12:40pm // SPEAKERS - Michael Salgaller, Director of Tech Transfer, NCI | Supervisor, Invention Development and Marketing Unit (IDMU); Steve Ferguson, Deputy Director, Licensing and Entrepreneurship, National Institutes of Health. TOPIC: Working with the NIH to Improve Pipe-Lines and Bottom-Lines
1:10pm // LUNCH BREAK / PANEL DISCUSSION
1:20pm // PANEL DISCUSSION: Approaches to Investing in the Oncology Space Through the Eyes of Various Investor Groups. Moderator: Dennis Purcell, Founder Aisling Capital. Panelists: Richard Lipkin, Managing Director, Easton Capital|Co-Founder, Catalytic Impact Foundation; John R. Prufeta, Founder & General Partner, Medical Excellence Capital; Peter Alff, Senior Venture Partner, Orange Grove Bio; Salvatore Buscemi, CEO and Co-Founding Partner, Harlem River Navy ("HRN")
2:00pm // Corporate Presentation - Nami Therapeutics
2:20pm // Corporate Presentation - BlueSky Immunotherapies
2:40pm // Corporate Presentation - Avstera Therapeutics
3:00pm // Corporate Presentation - Olive Healthcare
3:20pm // Corporate Presentation - Savor Health
3:40pm // Corporate Presentation - Humanetics Corp
4:00pm // Corporate Presentation - CairnSurgical
4:20pm // Corporate Presentation - BioTwin
4:40pm // Corporate Presentation - ConjugateBio
5:00pm // Corporate Presentation - Senex Biotechnology
5:20pm // SPEAKER - Catherine X. Pan-Giordano. Partner and Corporate Group Head at Dorsey & Whitney. Transactions in the Life Science Industry.
5:40pm // SPEAKER - Dr. Alexander Rudensky, Chairman of the Immunology Program at Memorial Sloan | Director, Ludwig Cancer Research. TOPIC: The Role of the Forkhead Family Transcription Factor Foxp3 in Establishing and Maintaining Immune Homeostasis
6:10pm // CLOSING REMARKS
6:20pm // COCKTAIL RECEPTION